Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary safety and efficacy endpoints. The study evaluated the WATCHMAN FLX™ ...

Physicians wrestled with endpoint composition, low event rates, a possible difference in ischemic strokes, and more.

CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.

Amidst the ongoing pressure, we are now upgrading Boston Scientific stock from hold to buy. Click here to read why.

Medical device manufacturer Boston Scientific Corp. (NYSE: BSX) is seemingly off to a tough start to the year, as shares have ...

We've got Chairman, President and CEO, Mike Mahoney; and Chief Medical Officer, Dr. Ken Stein here in Boston with the TD Cowen team. Thank you, guys. Yes. Sure. Good morning, everybody. Maybe a few ...

The noninferiority trial of patients at risk for both bleeding and stroke, in a surprise turn, found standard care to be ...

The battery problems behind a serious recall of Boston Scientific pacemakers have been ongoing for years, according to a New ...

SYRACUSE, N.Y. (WSYR-TV) — A Central New York man is sharing his story after decades of heart issues, and how a small device is helping protect his life. Simply being here today means everything for ...

Add Yahoo as a preferred source to see more of our stories on Google. Fred Hughes of Cicero says the WATCHMAN procedure changed his life, after battling decades of serious heart issues. Valerie ...

Explore how a 1992 Law & Order episode eerily mirrors Boston Scientific's real-life pacemaker battery issues, raising ...

In patients with atrial fibrillation, those assigned left atrial appendage closure had similar ischemic outcomes and better bleeding outcomes compared with those assigned oral anticoagulation, ...